Search

Displaying results 1521 - 1530 of 8517 in total
  1. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely … A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

    Categories: Bis-Trimethylammonium Compounds
  2. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.

  3. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

  4. Drug

    Dermatophagoides farinae

    go.drugbank.com/drugs/DB10400
    ApprovedInvestigational

    This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

  5. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

  6. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.

  7. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    acts as a highly selective potassium removing agent. … [L2933] The treatment effect was maintained for up to 12 months.[L2933]

  8. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

  9. Drug

    Urea C-13

    go.drugbank.com/drugs/DB09510
    ApprovedInvestigational

    Radiolabelled urea is available in two forms as 13C and 14C. … It is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as Pranactin-Citric) for the detection of Helicobacter pylori infections.

  10. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    [L8453,L8459] It was first approved for use in the United States in 2014. … such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.